Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$17.39 USD
+0.42 (2.47%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $17.40 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Arcus Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 759 | 1,009 | 499 | 729 | 188 |
Receivables | 38 | 39 | 747 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 34 | 19 | 16 | 5 | 4 |
Total Current Assets | 831 | 1,067 | 1,262 | 736 | 193 |
Net Property & Equipment | 51 | 35 | 32 | 11 | 9 |
Investments & Advances | 107 | 129 | 182 | 6 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 106 | 114 | 11 | 6 | 1 |
Total Assets | 1,095 | 1,345 | 1,592 | 772 | 203 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 17 | 20 | 10 | 16 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 54 | 28 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 167 | 173 | 102 | 78 | 8 |
Total Current Liabilities | 184 | 193 | 166 | 122 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 307 | 355 | 462 | 123 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 142 | 140 | 5 | 10 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 633 | 688 | 750 | 270 | 39 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1,311 | 1,206 | 0 | 0 | 0 |
Capital Surplus | 0 | 0 | 1,118 | 830 | 369 |
Retained Earnings | -849 | -542 | -275 | -328 | -205 |
Other Equity | 0 | -7 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 462 | 657 | 841 | 502 | 164 |
Total Liabilities & Shareholder's Equity | 1,095 | 1,345 | 1,592 | 772 | 203 |
Total Common Equity | 462 | 657 | 841 | 502 | 164 |
Shares Outstanding | 74.80 | 72.40 | 70.20 | 64.90 | 45.80 |
Book Value Per Share | 6.18 | 9.07 | 11.99 | 7.74 | 3.58 |
Fiscal Year End for Arcus Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 969 | 995 | 759 | 799 | 930 |
Receivables | 28 | 35 | 38 | 52 | 34 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 25 | 34 | 34 | 31 | 22 |
Total Current Assets | 1,022 | 1,064 | 831 | 882 | 986 |
Net Property & Equipment | 49 | 51 | 51 | 50 | 45 |
Investments & Advances | 40 | 100 | 107 | 151 | 80 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 75 | 78 | 106 | 108 | 109 |
Total Assets | 1,186 | 1,293 | 1,095 | 1,191 | 1,220 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 16 | 17 | 17 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 184 | 188 | 167 | 183 | 168 |
Total Current Liabilities | 199 | 204 | 184 | 200 | 180 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 214 | 242 | 307 | 326 | 330 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 138 | 142 | 145 | 144 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 551 | 586 | 633 | 671 | 654 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1,582 | 1,561 | 1,311 | 1,291 | 1,267 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -946 | -853 | -849 | -768 | -697 |
Other Equity | -1 | -1 | 0 | -3 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 635 | 707 | 462 | 520 | 566 |
Total Liabilities & Shareholder's Equity | 1,186 | 1,293 | 1,095 | 1,191 | 1,220 |
Total Common Equity | 635 | 707 | 462 | 520 | 566 |
Shares Outstanding | 90.90 | 90.90 | 74.80 | 74.50 | 73.10 |
Book Value Per Share | 6.99 | 7.78 | 6.18 | 6.98 | 7.74 |